# A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors

> **NCT06716138** · PHASE1 · RECRUITING · sponsor: **Avistone Biotechnology Co., Ltd.** · enrollment: 96 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration

## Interventions

- **DRUG:** ANS03

## Key facts

- **NCT ID:** NCT06716138
- **Lead sponsor:** Avistone Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-06
- **Primary completion:** 2027-12-30
- **Final completion:** 2029-03-30
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2026-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06716138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06716138, "A Study to Investigate ANS03 in Participants With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06716138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*